Dr. Michael Har-Noy, founder and CEO of Immunovative Therapies Ltd., says that the “Mirror EffectTM” is an immune mechanism that separates the beneficial graft versus tumor (GVT) effect of an allogeneic bone marrow transplant (BMT) from the often-lethal graft versus host disease (GVHD) side effect.
Dr. Michael Har-Noy separated these two immunologic events by creating a T-cell infusion that simulated the immune reactions caused by the transplanted donor cells but that was controlled by the patient's own immune cells. He says that this process, termed the Mirror EffectTM, can theoretically reproduce the curative treatment of a BMT without exposing the patient to potentially the life-threatening complication of GVHD.
Dr. Michael Har-Noy indicates that Mirror EffectTM mechanism reverses the intimately related GVT and GVHD reactions stemming from the infused graft cells. This effect originates from the patient's own immune system instead of from transplanted cells, thereby creating a “host versus tumor” (HVT) response associated with the non-toxic host versus graft (HVG) rejection mechanism. Dr. Michael Har-Noy says that in order to precipitate the “Mirror EffectTM”, T-cells from a normal donor are infused into a cancer patient. These donor T-cells then stimulate the patient's own immune response to attack the cancer (HVT effect) and create an inflammatory environment which incapacitates the tumor's immunoavoidance capabilities.
Dr. Michael Har-Noy indicates that since the HVT response must be linked to a HVG rejection, the patient must have an intact immune system that can mount a response to reject the donor T-cells. Additionally, since graft rejection (HVG) is desired, the donor cells need to be mismatched to the patient. This aspect of the treatment is a marked improvement over allogeneic BMT procedures, where only 33% of recipients have a suitably related donor.
The Mirror EffectTM, says Dr. Michael Har-Noy, therefore involves infusion of mismatched donor cells into a cancer patient that has not been pretreated. These infused cells are then rejected by the patient's immune system. This HVG reaction is the “mirror” of the lethal GVHD mechanism but is non-toxic. Dr. Michael Har-Noy adds that the HVG rejection precipitates host-mediated tumor lysis (HVT), which is the actual “mirror” of the GVT process. The Mirror EffectTM thus imitates the curative GVT effect of an allogeneic BMT while simultaneously avoiding the often-lethal GVHD .
Dr. Michael Har-Noy feels that the “Mirror EffectTM” may spawn an entire new field of cancer treatment. For more information about Dr. Michael Har-Noy's ongoing clinical trials and Compassionate Use program, please visit www.immunocare.net .